VNDA — Vanda Pharmaceuticals Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1347178 ·
Last close
$3.81
Market Cap
$230.39M
52W High
$9.94
52W Low
$3.57
ADV30
1,152,709
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 50,529,000 46,969,000 -63,809,000 -62,513,000 412,467,000 55,882,000 192,282,000
Mar 2026 51,718,000 48,559,000 -50,224,000 -48,567,000 433,525,000 54,034,000 152,760,000
Dec 2025 57,216,000 53,383,000 -40,353,000 -141,187,000 488,948,000 84,851,000 161,762,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-142,331,000
Investing CF
$120,272,000
Financing CF
$-2,789,000
CapEx
$-10,674,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.62
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-505,846,000
Inventory
$1,678,000
Receivables
$59,692,000
ST Investments
$114,147,000
EBIT TTM
$-185,670,000
Pretax Income TTM
$-177,200,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$229,278,000
EBITDA
$-169,107,008
Free Cash Flow
$-85,866,872
Enterprise Value
$110,657,112
Total Cash
$140,494,000
Total Debt
$21,971,000
Shares Out
60,469,687
Trailing EPS
$-4.63
Book Value
$5.54
ROE
-82.5%
ROA
-22.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 216,105,000 -151,168,000 -220,474,000 488,948,000 161,762,000 327,186,000 -109,442,000
Dec 2024 198,772,000 -40,660,000 -18,900,000 656,204,000 117,658,000 538,546,000 -15,757,000
Dec 2023 192,640,000 -13,952,000 2,509,000 648,440,000 103,530,000 544,910,000 12,801,000
Dec 2022 254,382,000 6,329,000 6,275,000 634,247,000 107,049,000 527,198,000 31,984,000

TTM Snapshot

Revenues TTM
$215,721,000
NetIncome TTM
$-274,853,000
OpCashFlow TTM
—
Assets (Latest)
$412,467,000
Forward EPS
$0.20

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $4.00 · spot: $3.75 · call volume: 113 · put volume: 20
Expected Move to 2026-12-18: ±$1.22 (32.53%) — implied range $2.53 – $4.97 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ARCT Arcturus Therapeutics Holdings Inc. $229.72M $7.97 —
FTH Faeth Therapeutics, Inc. $233.63M $9.04 —
BIOA BioAge Labs, Inc. $234.35M $5.10 —
RCKT ROCKET PHARMACEUTICALS, INC. $235.60M $2.11 —
IMRX Immuneering Corp $224.08M $3.46 —

News headlines (Yahoo Finance, 1h cache)

NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
2026-11-11 14:00 · Yahoo
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
2026-11-03 21:30 · Yahoo
Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
2026-11-01 13:02 · Yahoo
Vanda (VNDA) Q3 2026 Earnings Call Transcript
2026-10-29 05:44 · Yahoo
Vanda Pharmaceuticals Q3 Earnings Call Highlights
2026-10-29 00:04 · Yahoo
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
2026-10-28 20:20 · Yahoo
Vanda: Q3 Earnings Snapshot
2026-10-28 20:11 · Yahoo
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-10-28 20:01 · Yahoo
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
2026-10-27 10:50 · Yahoo
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
2026-10-21 21:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.